Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Science ; 358(6367)2017 12 01.
Article in English | MEDLINE | ID: mdl-29191879

ABSTRACT

Bone marrow-derived myeloid cells can accumulate within tumors and foster cancer outgrowth. Local immune-neoplastic interactions have been intensively investigated, but the contribution of the systemic host environment to tumor growth remains poorly understood. Here, we show in mice and cancer patients (n = 70) that lung adenocarcinomas increase bone stromal activity in the absence of bone metastasis. Animal studies reveal that the cancer-induced bone phenotype involves bone-resident osteocalcin-expressing (Ocn+) osteoblastic cells. These cells promote cancer by remotely supplying a distinct subset of tumor-infiltrating SiglecFhigh neutrophils, which exhibit cancer-promoting properties. Experimentally reducing Ocn+ cell numbers suppresses the neutrophil response and lung tumor outgrowth. These observations posit osteoblasts as remote regulators of lung cancer and identify SiglecFhigh neutrophils as myeloid cell effectors of the osteoblast-driven protumoral response.


Subject(s)
Adenocarcinoma/pathology , Antigens, CD/metabolism , Antigens, Differentiation, Myelomonocytic/metabolism , Bone and Bones/pathology , Lectins/metabolism , Lung Neoplasms/pathology , Neutrophil Infiltration , Neutrophils/metabolism , Neutrophils/pathology , Osteoblasts/pathology , Adenocarcinoma of Lung , Animals , Bone Density , Bone Marrow Cells/pathology , Bone and Bones/metabolism , Cell Line, Tumor , Humans , Mice , Mice, Inbred C57BL , Myeloid Cells/pathology , Neoplasms, Experimental/pathology , Osteocalcin/metabolism , Receptor for Advanced Glycation End Products/metabolism
2.
Cell Rep ; 17(7): 1764-1772, 2016 11 08.
Article in English | MEDLINE | ID: mdl-27829148

ABSTRACT

Co-option of host components by solid tumors facilitates cancer progression and can occur in both local tumor microenvironments and remote locations. At present, the signals involved in long-distance communication remain insufficiently understood. Here, we identify platelet factor 4 (PF4, CXCL4) as an endocrine factor whose overexpression in tumors correlates with decreased overall patient survival. Furthermore, engineered PF4 over-production in a Kras-driven lung adenocarcinoma genetic mouse model expanded megakaryopoiesis in bone marrow, augmented platelet accumulation in lungs, and accelerated de novo adenocarcinogenesis. Additionally, anti-platelet treatment controlled mouse lung cancer progression, further suggesting that platelets can modulate the tumor microenvironment to accelerate tumor outgrowth. These findings support PF4 as a cancer-enhancing endocrine signal that controls discrete aspects of bone marrow hematopoiesis and tumor microenvironment and that should be considered as a molecular target in anticancer therapy.


Subject(s)
Blood Platelets/metabolism , Lung Neoplasms/blood , Lung Neoplasms/pathology , Platelet Factor 4/metabolism , Adenocarcinoma/blood , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Animals , Bone Marrow Cells/metabolism , Carcinogenesis/metabolism , Carcinogenesis/pathology , Cell Lineage , Cell Proliferation , Disease Progression , Humans , Megakaryocytes/metabolism , Mice , Proto-Oncogene Proteins p21(ras)/metabolism , Survival Analysis
3.
Science ; 352(6282): 242-6, 2016 Apr 08.
Article in English | MEDLINE | ID: mdl-26989197

ABSTRACT

Tumor-derived extracellular vesicles (tEVs) are important signals in tumor-host cell communication, yet it remains unclear how endogenously produced tEVs affect the host in different areas of the body. We combined imaging and genetic analysis to track melanoma-derived vesicles at organismal, cellular, and molecular scales to show that endogenous tEVs efficiently disseminate via lymphatics and preferentially bind subcapsular sinus (SCS) CD169(+) macrophages in tumor-draining lymph nodes (tdLNs) in mice and humans. The CD169(+) macrophage layer physically blocks tEV dissemination but is undermined during tumor progression and by therapeutic agents. A disrupted SCS macrophage barrier enables tEVs to enter the lymph node cortex, interact with B cells, and foster tumor-promoting humoral immunity. Thus, CD169(+) macrophages may act as tumor suppressors by containing tEV spread and ensuing cancer-enhancing immunity.


Subject(s)
B-Lymphocytes/immunology , Extracellular Vesicles/immunology , Immune Tolerance , Macrophages/immunology , Melanoma/immunology , Skin Neoplasms/immunology , Animals , B-Lymphocytes/ultrastructure , Cell Communication , Humans , Lymph Nodes/immunology , Lymphatic Vessels/immunology , Macrophages/chemistry , Melanoma/pathology , Melanoma, Experimental/immunology , Melanoma, Experimental/pathology , Mice , Mice, Inbred C57BL , Sialic Acid Binding Ig-like Lectin 1/analysis , Sialic Acid Binding Ig-like Lectin 1/immunology , Skin Neoplasms/pathology
4.
Immunity ; 44(2): 343-54, 2016 Feb 16.
Article in English | MEDLINE | ID: mdl-26872698

ABSTRACT

Checkpoint blockade immunotherapies can be extraordinarily effective, but might benefit only the minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung adenocarcinoma mouse models, including genetic models, we show that autochthonous tumors that lacked T cell infiltration and resisted current treatment options could be successfully sensitized to host antitumor T cell immunity when appropriately selected immunogenic drugs (e.g., oxaliplatin combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and lacking Trp53) were used. The antitumor response was triggered by direct drug actions on tumor cells, relied on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended on CD8(+) T cell antitumor immunity. Furthermore, instigating tumor infiltration by T cells sensitized tumors to checkpoint inhibition and controlled cancer durably. These findings indicate that the proportion of cancers responding to checkpoint therapy can be feasibly and substantially expanded by combining checkpoint blockade with immunogenic drugs.


Subject(s)
Adenocarcinoma/therapy , CD8-Positive T-Lymphocytes/drug effects , Immunotherapy/methods , Lung Neoplasms/therapy , Lymphocytes, Tumor-Infiltrating/drug effects , Adenocarcinoma/immunology , Animals , Cell Line, Tumor , Central Nervous System Sensitization/drug effects , Cyclophosphamide/administration & dosage , Disease Models, Animal , Drug Therapy/methods , Genes, cdc/drug effects , Humans , Immunity, Innate , Lung Neoplasms/immunology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Organoplatinum Compounds/administration & dosage , Oxaliplatin , Toll-Like Receptor 4/metabolism
5.
Immunity ; 38(2): 296-308, 2013 Feb 21.
Article in English | MEDLINE | ID: mdl-23333075

ABSTRACT

Macrophages frequently infiltrate tumors and can enhance cancer growth, yet the origins of the macrophage response are not well understood. Here we address molecular mechanisms of macrophage production in a conditional mouse model of lung adenocarcinoma. We report that overproduction of the peptide hormone Angiotensin II (AngII) in tumor-bearing mice amplifies self-renewing hematopoietic stem cells (HSCs) and macrophage progenitors. The process occurred in the spleen but not the bone marrow, and was independent of hemodynamic changes. The effects of AngII required direct hormone ligation on HSCs, depended on S1P(1) signaling, and allowed the extramedullary tissue to supply new tumor-associated macrophages throughout cancer progression. Conversely, blocking AngII production prevented cancer-induced HSC and macrophage progenitor amplification and thus restrained the macrophage response at its source. These findings indicate that AngII acts upstream of a potent macrophage amplification program and that tumors can remotely exploit the hormone's pathway to stimulate cancer-promoting immunity.


Subject(s)
Adenocarcinoma/metabolism , Angiotensin II/genetics , Carcinoma, Non-Small-Cell Lung/metabolism , Lung Neoplasms/metabolism , Macrophages/metabolism , Spleen/metabolism , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adenocarcinoma of Lung , Angiotensin II/metabolism , Animals , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Cell Communication , Cell Movement , Cell Proliferation , Gene Expression , Hematopoietic Stem Cells/metabolism , Hematopoietic Stem Cells/pathology , Humans , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Lysophospholipids/metabolism , Macrophages/pathology , Mice , Mice, Transgenic , Signal Transduction , Sphingosine/analogs & derivatives , Sphingosine/metabolism , Spleen/pathology , Tumor Burden
6.
Cell Rep ; 1(4): 317-24, 2012 Apr 19.
Article in English | MEDLINE | ID: mdl-22545247

ABSTRACT

Monocytes serve as a central defense system against infection and injury but can also promote pathological inflammatory responses. Considering the evidence that monocytes exist in at least two subsets committed to divergent functions, we investigated whether distinct factors regulate the balance between monocyte subset responses in vivo. We identified a microRNA (miRNA), miR-146a, which is differentially regulated both in mouse (Ly-6C(hi)/Ly-6C(lo)) and human (CD14(hi)/CD14(lo)CD16(+)) monocyte subsets. The single miRNA controlled the amplitude of the Ly-6C(hi) monocyte response during inflammatory challenge whereas it did not affect Ly-6C(lo) cells. miR-146a-mediated regulation was cell-intrinsic and depended on Relb, a member of the noncanonical NF-κB/Rel family, which we identified as a direct miR-146a target. These observations not only provide mechanistic insights into the molecular events that regulate responses mediated by committed monocyte precursor populations but also identify targets for manipulating Ly-6C(hi) monocyte responses while sparing Ly-6Clo monocyte activity.


Subject(s)
MicroRNAs/physiology , Monocytes/physiology , Transcription Factor RelB/physiology , Animals , Cell Movement , Cell Proliferation , Gene Expression Regulation , Humans , Mice , Monocytes/immunology , Monocytes/metabolism , Transcription Factor RelB/metabolism
7.
Proc Natl Acad Sci U S A ; 109(7): 2491-6, 2012 Feb 14.
Article in English | MEDLINE | ID: mdl-22308361

ABSTRACT

Tumor-associated macrophages (TAMs) and tumor-associated neutrophils (TANs) can control cancer growth and exist in almost all solid neoplasms. The cells are known to descend from immature monocytic and granulocytic cells, respectively, which are produced in the bone marrow. However, the spleen is also a recently identified reservoir of monocytes, which can play a significant role in the inflammatory response that follows acute injury. Here, we evaluated the role of the splenic reservoir in a genetic mouse model of lung adenocarcinoma driven by activation of oncogenic Kras and inactivation of p53. We found that high numbers of TAM and TAN precursors physically relocated from the spleen to the tumor stroma, and that recruitment of tumor-promoting spleen-derived TAMs required signaling of the chemokine receptor CCR2. Also, removal of the spleen, either before or after tumor initiation, reduced TAM and TAN responses significantly and delayed tumor growth. The mechanism by which the spleen was able to maintain its reservoir capacity throughout tumor progression involved, in part, local accumulation in the splenic red pulp of typically rare extramedullary hematopoietic stem and progenitor cells, notably granulocyte and macrophage progenitors, which produced CD11b(+) Ly-6C(hi) monocytic and CD11b(+) Ly-6G(hi) granulocytic cells locally. Splenic granulocyte and macrophage progenitors and their descendants were likewise identified in clinical specimens. The present study sheds light on the origins of TAMs and TANs, and positions the spleen as an important extramedullary site, which can continuously supply growing tumors with these cells.


Subject(s)
Macrophages/immunology , Neoplasms/pathology , Neutrophils/immunology , Animals , Humans , Mice , Neoplasms/immunology , Spleen/immunology , Spleen/pathology
8.
Bioconjug Chem ; 22(12): 2383-9, 2011 Dec 21.
Article in English | MEDLINE | ID: mdl-22035047

ABSTRACT

Tissue macrophages play a critical role both in normal physiology and in disease states. However, because of a lack of specific imaging agents, we continue to have a poor understanding of their absolute numbers, flux rates, and functional states in different tissues. Here, we describe a new macrophage specific positron emission tomography imaging agent, labeled with zirconium-89 ((89)Zr), that was based on a cross-linked, short chain dextran nanoparticle (13 nm). Following systemic administration, the particle demonstrated a vascular half-life of 3.9 h and was found to be located primarily in tissue resident macrophages rather than other white blood cells. Subsequent imaging of the probe using a xenograft mouse model of cancer allowed for quantitation of tumor-associated macrophage numbers, which are of major interest in emerging molecular targeting strategies. It is likely that the material described, which allows the visualization of macrophage biology in vivo, will likewise be useful for a multitude of human applications.


Subject(s)
Dextrans/chemistry , Macrophages/cytology , Nanoparticles , Neoplasms/diagnosis , Positron-Emission Tomography/methods , Zirconium , Animals , Cell Line, Tumor , Half-Life , Humans , Isotopes/analysis , Mice , Nanoparticles/chemistry , Zirconium/analysis
9.
Nat Biotechnol ; 29(11): 1005-10, 2011 Oct 09.
Article in English | MEDLINE | ID: mdl-21983520

ABSTRACT

Excessive and prolonged activity of inflammatory monocytes is a hallmark of many diseases with an inflammatory component. In such conditions, precise targeting of these cells could be therapeutically beneficial while sparing many essential functions of the innate immune system, thus limiting unwanted effects. Inflammatory monocytes-but not the noninflammatory subset-depend on the chemokine receptor CCR2 for localization to injured tissue. Here we present an optimized lipid nanoparticle and a CCR2-silencing short interfering RNA that, when administered systemically in mice, show rapid blood clearance, accumulate in spleen and bone marrow, and localize to monocytes. Efficient degradation of CCR2 mRNA in monocytes prevents their accumulation in sites of inflammation. Specifically, the treatment attenuates their number in atherosclerotic plaques, reduces infarct size after coronary artery occlusion, prolongs normoglycemia in diabetic mice after pancreatic islet transplantation, and results in reduced tumor volumes and lower numbers of tumor-associated macrophages.


Subject(s)
Gene Silencing , Inflammation/therapy , Macrophages/drug effects , Nanoparticles , RNA, Small Interfering/therapeutic use , Receptors, CCR2/antagonists & inhibitors , Animals , Atherosclerosis/therapy , Blood Glucose , Diabetes Mellitus/surgery , Diabetes Mellitus/therapy , Disease Models, Animal , Graft Survival/genetics , Humans , Islets of Langerhans Transplantation , Mice , Mice, Inbred C57BL , Monocytes/metabolism , Myocardial Infarction/prevention & control , Myocardial Infarction/therapy , Nanoparticles/chemistry , Receptors, CCR2/genetics
10.
Lab Chip ; 11(1): 147-51, 2011 Jan 07.
Article in English | MEDLINE | ID: mdl-20949198

ABSTRACT

We have developed a compact and inexpensive microfluidic chip, the self-assembled magnetic filter, to efficiently remove magnetically tagged cells from suspension. The self-assembled magnetic filter consists of a microfluidic channel built directly above a self-assembled NdFeB magnet. Micrometre-sized grains of NdFeB assemble to form alternating magnetic dipoles, creating a magnetic field with a very strong magnitude B (from the material) and field gradient ▽B (from the configuration) in the microfluidic channel. The magnetic force imparted on magnetic beads is measured to be comparable to state-of-the-art microfabricated magnets, allowing for efficient separations to be performed in a compact, simple device. The efficiency of the magnetic filter is characterized by sorting non-magnetic (polystyrene) beads from magnetic beads (iron oxide). The filter enriches the population of non-magnetic beads to magnetic beads by a factor of >10(5) with a recovery rate of 90% at 1 mL h(-1). The utility of the magnetic filter is demonstrated with a microfluidic device that sorts tumor cells from leukocytes using negative immunomagnetic selection, and concentrates the tumor cells on an integrated membrane filter for optical detection.


Subject(s)
Immunomagnetic Separation/instrumentation , Microfluidic Analytical Techniques/instrumentation , Animals , Cell Line, Tumor , Equipment Design , Humans , Immunomagnetic Separation/economics , Leukocytes/cytology , Mice , Microfluidic Analytical Techniques/economics
11.
Neoplasia ; 11(5): 459-68, 2 p following 468, 2009 May.
Article in English | MEDLINE | ID: mdl-19412430

ABSTRACT

Tumor-associated macrophages (TAMs) invade the tumor stroma in many cancers, yet their role is incompletely understood. To visualize and better understand these critical cells in tumor progression, we screened a portfolio of rationally selected, injectable agents to image endogenous TAMs ubiquitously in three different cancer models (colon carcinoma, lung adenocarcinoma, and soft tissue sarcoma). AMTA680, a functionally derivatized magneto-fluorescent nanoparticle, labeled a subset of myeloid cells with an "M2" macrophage phenotype, whereas other neighboring cells, including tumor cells and a variety of other leukocytes, remained unlabeled. We further show that AMTA680-labeled endogenous TAMs are not altered and can be tracked noninvasively at different resolutions and using various imaging modalities, e.g., fluorescence molecular tomography, magnetic resonance imaging, and multiphoton and confocal intravital microscopy. Quantitative assessment of TAM distribution and activity in vivo identified that these cells cluster in delimited foci within tumors, show relatively low motility, and extend cytoplasmic protrusions for prolonged physical interactions with neighboring tumor cells. Noninvasive imaging can also be used to monitor TAM-depleting regimen quantitatively. Thus, AMTA680 or related cell-targeting agents represent appropriate injectable vehicles for in vivo analysis of the tumor microenvironment.


Subject(s)
Diagnostic Imaging/methods , Macrophages/cytology , Metal Nanoparticles , Neoplasms/immunology , Animals , Immunohistochemistry , Magnetic Resonance Imaging , Mice , Microscopy, Confocal , Reverse Transcriptase Polymerase Chain Reaction
12.
J Clin Invest ; 118(12): 4058-66, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19033674

ABSTRACT

Eosinophils are multifunctional leukocytes that degrade and remodel tissue extracellular matrix through production of proteolytic enzymes, release of proinflammatory factors to initiate and propagate inflammatory responses, and direct activation of mucus secretion and smooth muscle cell constriction. Thus, eosinophils are central effector cells during allergic airway inflammation and an important clinical therapeutic target. Here we describe the use of an injectable MMP-targeted optical sensor that specifically and quantitatively resolves eosinophil activity in the lungs of mice with experimental allergic airway inflammation. Through the use of real-time molecular imaging methods, we report the visualization of eosinophil responses in vivo and at different scales. Eosinophil responses were seen at single-cell resolution in conducting airways using near-infrared fluorescence fiberoptic bronchoscopy, in lung parenchyma using intravital microscopy, and in the whole body using fluorescence-mediated molecular tomography. Using these real-time imaging methods, we confirmed the immunosuppressive effects of the glucocorticoid drug dexamethasone in the mouse model of allergic airway inflammation and identified a viridin-derived prodrug that potently inhibited the accumulation and enzyme activity of eosinophils in the lungs. The combination of sensitive enzyme-targeted sensors with noninvasive molecular imaging approaches permitted evaluation of airway inflammation severity and was used as a model to rapidly screen for new drug effects. Both fluorescence-mediated tomography and fiberoptic bronchoscopy techniques have the potential to be translated into the clinic.


Subject(s)
Androstenes/pharmacology , Anti-Inflammatory Agents/pharmacology , Bacteriocins/pharmacology , Bronchoscopy/methods , Dexamethasone/pharmacology , Prodrugs/pharmacology , Respiratory Hypersensitivity/drug therapy , Respiratory Hypersensitivity/pathology , Tomography, Optical/methods , Androstenes/therapeutic use , Animals , Anti-Inflammatory Agents/therapeutic use , Bacteriocins/therapeutic use , Dexamethasone/therapeutic use , Disease Models, Animal , Drug Evaluation, Preclinical/methods , Eosinophils/enzymology , Eosinophils/pathology , Inflammation/drug therapy , Inflammation/enzymology , Inflammation/pathology , Inflammation/physiopathology , Lung/enzymology , Lung/pathology , Lung/physiopathology , Mice , Mice, Inbred BALB C , Mice, Mutant Strains , Muscle Contraction/drug effects , Muscle, Smooth/enzymology , Muscle, Smooth/pathology , Prodrugs/therapeutic use , Respiratory Hypersensitivity/enzymology , Respiratory Hypersensitivity/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...